P11-4

In plain language

P11-4 is a small peptide designed to help minerals build back into areas of early tooth decay. It is used in a dental system called Curodont Repair, which is intended for lesions that have not developed an open cavity. (Mechanism review, professional product information)

Think of it as a tiny framework that helps minerals collect where enamel has weakened. It does not fill an existing hole, rebuild a missing tooth or remove the need for dental assessment. (Mechanism review, manufacturer’s treatment limitations)

For students

Enamel can lose minerals during the development of an early carious lesion, sometimes producing a white-spot appearance. P11-4 is designed to diffuse into this porous lesion and self-assemble into a three-dimensional scaffold that supports the formation of hydroxyapatite, the principal mineral in enamel. (Mechanism review)

The scaffold helps organize mineral deposition using calcium and phosphate available in the surrounding environment, including saliva. This is guided remineralization within an early lesion, not the growth of a new tooth or proof that extensive structural damage can be replaced. (Mechanism review, professional product information)

Evidence and limitations

P11-4 is described in the literature as an 11-residue peptide with the sequence Ac–QQRFEWEFEQQ–NH₂, including an acetylated N-terminus and an amidated C-terminus. Local conditions within a lesion support its assembly into a fibrillar scaffold that promotes mineral nucleation and growth. (Peer-reviewed sequence and mechanism)

A 2023 JADA systematic review included six clinical trials and reported that Curodont Repair likely increased caries arrest, with a risk ratio of 1.82 and a 95% confidence interval of 1.32–2.50. However, all included trials had elevated risks of bias, two had unmasked assessors, and the authors recommended longer follow-up. (JADA review)

The same review’s estimate for cavitation was less conclusive: its confidence interval included the possibility of no difference. The review also included no trials of Curodont Repair Fluoride Plus, so its estimates must not be transferred automatically to every Curodont formulation. (JADA review)

A separate randomized trial published in January 2026 enrolled 25 adolescents undergoing fixed-brace treatment and studied a P11-4-containing prevention gel against a fluoride-containing placebo gel. At 18 months, initial lesions were reported on 7.2% versus 14.5% of examined surfaces, but these are surface-level percentages, not percentages of participants, and the authors emphasized the small sample and limited patient-level power. (2026 orthodontic trial)

That prevention-gel study is not a trial of the dentist-applied liquid for treating existing lesions. Its findings should be described separately rather than presented as confirmation that all P11-4 products have identical benefits. (Trial formulations and limitations)